ERBB2 and breast carcinoma: While treatment options for breast cancer varies depending on the differentiated subtypes, trastuzumab remains one of the common therapeutic regimens, a humanized monoclonal antibody engineered to specifically target human epidermal growth factor receptor 2 (HER2) proteins (Kitani et al., 2019; Waks and Winer, 2019)